Quantum BioPharma Ltd., together with its subsidiaries, operates as a biopharmaceutical company. The company operates through two segments, Biopharmaceutical Innovation and Strategic Investments. It researches and develops a portfolio of assets and biotech solutions for the treatment of neurodegenerative, inflammatory …
| Periodo | 2026-05 | 2025-11 | 2022-03 | 2020-11 |
|---|---|---|---|---|
| Real | $-4.17 | $-1.77 | $-10.55 | $-84.50 |
| Estimado | $-0.68 | $-3.70 | $-68.25 | $-46.48 |
| Sorpresa | -513.2% | +52.2% | +84.5% | -81.8% |
| Métrica | QNTM | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.4% | — |
| Operating Margin | — | -34.4% | — |
| Net Margin | — | -32.5% | — |
| FCF Margin | — | -12.6% | — |
| ROE | — | -39.2% | — |
| ROA | — | -30.9% | — |
| Current Ratio | 1.07 | 2.73 | -1.66 |
| Debt / Equity | — | 0.28 | — |
| Tendencia (Piotroski) | FY25 | FY24 |
|---|---|---|
| ✗Rentabilidad sobre activos positiva | — | — |
| ✗Flujo de caja operativo positivo | −$8M | −$7M |
| –Rentabilidad sobre activos al alza | — | — |
| –Caja operativa/activos supera al ROA | -73.8% | — |
| –Menos deuda a largo plazo | — | — |
| ✗Mejor liquidez (ratio corriente) | 1.07 | 1.80 |
| ✗Sin aumentar el nº de acciones | — | 1M |
| –Margen bruto al alza | — | — |
| –Rotación de activos al alza | — | — |
| Calidad del negocio | FY25 |
|---|---|
| ✗ROCE > 10 % | -299.9% |
| ✓Deuda neta/EBITDA < 3x | Caja neta |
Quantum Biopharma Ltd. cotiza a 2.47 USD y tiene una capitalización bursátil de $16M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud